Working… Menu

A Single-dose Escalation Safety and PK Study for PLC in Healthy Chinese

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02786069
Recruitment Status : Completed
First Posted : May 30, 2016
Last Update Posted : May 30, 2016
Information provided by (Responsible Party):
Lee's Pharmaceutical Limited

Tracking Information
First Submitted Date  ICMJE May 24, 2016
First Posted Date  ICMJE May 30, 2016
Last Update Posted Date May 30, 2016
Study Start Date  ICMJE June 2015
Actual Primary Completion Date November 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 25, 2016)
Area Under Curve (AUC) [ Time Frame: 0h, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16 and 24h after administration ]
To observe area under curve characteristics of propionyl L-carnitine hydrochloride in single dose oral 1, 2, 4g
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: May 25, 2016)
cumulative excretion percentage [ Time Frame: after drinking 0-2h, 2-4h, 4-8h, 8-12h, 12-24h for 4ml urine collection ]
To estimate cumulative excretion percentage from the urine drug concentration in single dose oral 1, 2, 4g propionyl L-carnitine hydrochloride tablets
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE A Single-dose Escalation Safety and PK Study for PLC in Healthy Chinese
Official Title  ICMJE A Single-arm, Self-controlled, Three-period Dynamics Single-dose Escalation Safety and Pharmacokinetics Study for Propionyl L-carnitine Hydrochloride Tablets of Healthy Subjects in China
Brief Summary The main objective is to evaluate the effect of single dose Propionyl-L-Carnitine Hydrochloride on clinical pharmacokinetic characteristics and its effect of clinical pharmacokinetic characteristics and safety on healthy Chinese subjects to provide a basis for market authorization registration.
Detailed Description

Before the official start of the study, to determine the appropriate dosing interval and a preliminary assessment of drug safety, first carried out the pre-trial, 4 subjects with different gender in half, after 7 days of run-in period, collect baseline background sampling point at day 4, no medication but water intake. At day 8 fasting oral propionyl L-carnitine hydrochloride tablets 0.5g, according to pre-designed schedule for blood samples, urine samples and clinical indicators, provide a reference for official trial.

Official trial is a single, open label, self-controlled, three-period, dose escalation, period fasting single oral administration trial. 12 chinese healthy adult subject met the inclusion criteria 12 people, each gender in half. Each subject first pass 7 days of run-in period, to eliminate the residual substances in food L-carnitine, stable baseline level of endogenous L-carnitine class substance within the subject; at day 4 was baseline sampling point, tno medication but water intake; at day 8 (1st period day 1) fasting oral propionyl L-carnitine hydrochloride tablets 1g; at day 12 (2nd period of day 1) fasting oral hydrochloride propionyl L-carnitine tablets 2g; the first 16 days (3rd period day 1) fasting oral propionyl L-carnitine hydrochloride tablets 4g.Throughout the trial period, control the subjects' diet, eating only allowed as far as possible food without substance L-carnitine class and drink boiled water,diet at sampling day 4, 8, 12, 16 need to be fixed consistently. Every 4 days of dosing interval washout period.

Subject need to follow blood, urine collection and diet control as required by protocol before the day of run-in period. During the trial should avoid vigorous exercise, meanwhile to avoid long-time bedding.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Peripheral Arterial Disease
Intervention  ICMJE Drug: Propionyl L-carnitine Hydrochloride
500mg/ tablet; for oral administration, 1 dosage form is set for this trial: 1g, 2g and 4g.
Study Arms  ICMJE Experimental: Single arm
Intervention: Drug: Propionyl L-carnitine Hydrochloride
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 25, 2016)
Original Actual Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE January 2016
Actual Primary Completion Date November 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Gender: male and female, healthy subjects;
  • Age: 19 to 45 years of age, of similar age;
  • Weight: The weight of all subjects need ≥50 kg, body mass index [BMI = weight (kg) / height 2 (m 2)] within 19 to 24 kg / m2 range of weight as close as possible;
  • Blood pressure: SBP 90-139mmHg, DBP 60-89 mmHg;
  • The subjects must be informed consent before the trial, and voluntarily signed a written informed consent form;
  • Subjects can be good communication with researchers and to complete the test in accordance with program requirements.

Exclusion Criteria:

Subjects having one or more cannot be selected for the trial:

Laboratory parameters:

  • Before testing the safety evaluation of any one of the researchers baseline values considered clinically significant abnormalities;
  • Hepatitis B surface antigen test positive;
  • Hepatitis C antibody test positive;
  • AIDS, syphilis testing positive;
  • Pre-medication ECG abnormal situation at screening period or trial day 1 as followings:
  • QTc> 450 ms (QTc using Bazett correction formula QTc = QT / RR0.5 computing);
  • Ⅱ ° atrioventricular or Ⅲ ° atrioventricular block;
  • heart rate <45 beats / min or> 100 beats / min;
  • Room PR of> 200 ms or <110 ms;
  • QRS complex> 120 ms;
  • Pathological Q waves (in accordance with Q wave> 40 ms defined);
  • Ventricular pre-excitation syndrome;

Medication history:

  • 1 month before the trial orally used any inhibition or induction of hepatic drug metabolism of drugs;
  • 2 weeks before the trial taking any medications (including prescription and non-prescription drugs and herbal preparations) persons;

Disease history and surgical history:

  • Past history of suffering from structural heart disease, arrhythmias, heart failure, history of history, history of myocardial infarction, angina pectoris, history cannot be explained, fast ventricular reverse history, history of ventricular tachycardia, QT prolongation syndrome or have a history of long QT syndrome symptoms and family history (as evidenced by genetic or close relative at a young age due to cardiac causes of sudden death show);
  • Have a history of thyroid disease or previously treated thyroid surgery;
  • A history of immune system (such as a history of thymus disease);
  • Within six months before the trial had received surgery;
  • Have a history of severe digestive system diseases (such as having a significant clinical significance of gallbladder disease, known or suspected jaundice, hepatocellular adenoma, cavernous hemangioma of the liver and other liver diseases);
  • Within six months before the trial have suffered from gastrointestinal or metabolic liver and kidney disease that can affect drug absorption (whether or not cured were excluded);
  • Have any serious cardiovascular system, respiratory system, metabolic system and the nervous system a history;
  • Suffering from blood coagulation disorders and other diseases system;
  • Have a history of cancer;
  • According to a clinical laboratory reference range limits, with hypokalemia, hypocalcemia;


  • Within six months before the trial frequent drinkers, that drinking more than 14 units of alcohol a week (1 unit = 17.7 ml ethanol, or 1 unit = 357 ml alcohol content of 5% of the amount of alcohol in beer or 44 ml of 40% spirits or 147 ml alcohol content of 12% of the wine);
  • Within three months before the trial daily cigarette consumption> one;
  • Before the trial, 1 year history of drug abuse and drug taking too (such as marijuana, cocaine, opiates, benzodiazepines, amphetamines, barbiturates, tricyclic antidepressants, etc.);
  • Before treatment 2 days to 8 days after drug overdose drinking tea, coffee and / or beverages containing caffeine (8 cups or more) every day;
  • Eight days before treatment were drinking grapefruit juice and other beverages to medication after two days;


  • Do not agree to take effective contraceptive measures after medication within 3 months;
  • Allergies, including known allergies history to this drug excipients (microcrystalline cellulose, lactose, silica powder, sodium carboxymethyl starch, magnesium stearate);
  • Within three months before the trial participated in any clinical trials or after the enrollment of this trial until 1 month after the end of the last follow-up visit to participate in other clinical trials;
  • Before the trial within three months have donated blood, or planned to do so after until 1 month of the end of last follow-up visit;
  • Have any food allergies or special dietary requirements, cannot comply with unified diets;
  • The researchers judgments that those who should not be included;

Female subjects in addition to the above criteria, fulfilling any one of the following criteria must be excluded:

  • Taking oral contraceptives before 1 month of trial;
  • The use of long-acting estrogen or progestin injections or implants before 6 months of trial;
  • Women of childbearing age failed to take adequate contraceptive measures before 2 weeks of trial;
  • Women of childbearing age and their spouses do not agree to take following contraception measures within three months after medication: condoms, IUD;
  • Pregnancy, lactation ;
  • Urine pregnancy test was positive;
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 19 Years to 45 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT02786069
Other Study ID Numbers  ICMJE Zhaoke-201506-PLC-single dose
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Lee's Pharmaceutical Limited
Study Sponsor  ICMJE Lee's Pharmaceutical Limited
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Heng-yan Qu National Clinical Trial Institution of Affiliated Hospital of Military Medical Sciences
PRS Account Lee's Pharmaceutical Limited
Verification Date April 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP